New hope for advanced breast cancer patients after hormone therapy fails

NCT ID NCT06635447

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding the experimental drug capivasertib to standard fulvestrant treatment helps control advanced breast cancer that has worsened after hormone therapy. It involves about 258 Chinese patients with specific genetic changes in their tumors. The main goal is to see if this combination delays the need for the next cancer treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Baoding, 071000, China
Research Site

Beijing, 100021, China
Research Site

Beijing, 100071, China
Research Site

Beijing, 100730, China
Research Site

Beijing, CN-100730, China
Research Site

Bengbu, 233004, China
Research Site

Changchun, 130021, China
Research Site

Changsha, 410008, China
Research Site

Changsha, 410011, China
Research Site

Changsha, 410013, China
Research Site

Chengdu, 610072, China
Research Site

Dalian, 116001, China
Research Site

Dalian, China
Research Site

Deyang, 618000, China
Research Site

Dongguan, 523009, China
Research Site

Foshan, 528000, China
Research Site

Fuzhou, 350001, China
Research Site

Fuzhou, 350011, China
Research Site

Guangzhou, 510060, China
Research Site

Guangzhou, 510120, China
Research Site

Guiyang, 550044, China
Research Site

Hangzhou, 310003, China
Research Site

Hangzhou, 310009, China
Research Site

Hangzhou, 310016, China
Research Site

Hangzhou, 310022, China
Research Site

Harbin, 150081, China
Research Site

Hefei, 230022, China
Research Site

Hefei, 230031, China
Research Site

Huizhou, 516001, China
Research Site

Jinan, 250012, China
Research Site

Jinhua, China
Research Site

Jining, 272029, China
Research Site

Kashgar, 844099, China
Research Site

Kunming, 650118, China
Research Site

Linhai, 317000, China
Research Site

Meizhou, 514031, China
Research Site

Nanchang, 330009, China
Research Site

Nanchong, 637000, China
Research Site

Nanjing, 210029, China
Research Site

Ningbo, 315099, China
Research Site

Ningbo, 315100, China
Research Site

Qingdao, 266042, China
Research Site

Shanghai, 200025, China
Research Site

Shanghai, 200080, China
Research Site

Shanghai, 201114, China
Research Site

Shanghai, 201210, China
Research Site

Shantou, 515063, China
Research Site

Shenyang, 110004, China
Research Site

Shenyang, 110042, China
Research Site

Shenzhen, 518020, China
Research Site

Shenzhen, 518036, China
Research Site

Shijiazhuang, 050020, China
Research Site

Sichuan, 610041, China
Research Site

Suining Shi, 629000, China
Research Site

Suzhou, 215004, China
Research Site

Taiyuan, 030000, China
Research Site

Tangshan, 063001, China
Research Site

Tianjin, 300060, China
Research Site

Ürümqi, 830000, China
Research Site

Ürümqi, 830054, China
Research Site

Wanzhou, 404000, China
Research Site

Weifang, 261000, China
Research Site

Wenzhou, 325000, China
Research Site

Wuhan, 430022, China
Research Site

Wuhan, 430030, China
Research Site

Xi'an, 710000, China
Research Site

Xi'an, 710006, China
Research Site

Xi'an, 710061, China
Research Site

Xiamen, 361003, China
Research Site

Xuzhou, 221005, China
Research Site

Yinchuan, 750000, China
Research Site

Zhanjiang, 524004, China
Research Site

Zhengzhou, 450000, China
Research Site

Zhengzhou, 450008, China
Research Site

Zhengzhou, 450052, China

Conditions

Explore the condition pages connected to this study.

BREAST CANCER